Inclusion criteria:
1. Inoperable stage IIIb/IV histologically /cytologically confirmed lung adenocarcinoma
2. PD-L1 expression ALK mutation negative
3. Patients with unmeasurable but evaluable disease can be included in the phase I study, but disease must be measurable to be included in the phase II study.
4. ECOG performance status of 0 or 1
5. Age at least 18 years
6. Adequate haematological status: Haemoglobin 100g/L or greater; Neutrophil count ≥1.5 x 10^9/L, Platelets ≥100 x 10^9 /L
7. Adequate organ function: Bilirubin ≤1.5 x ULN; ALT or AST ≤3 x ULN; Creatinine clearance ≥ 60 ml/min
Exclusion criteria
1. Prior chemotherapy, hormonal therapy, radiotherapy (including palliative radiotherapy), immunotherapy or treatment with
investigational drugs for advanced NSCLC; prior treatment with any cellular therapy; any surgical procedure in the previous 6 weeks
2. Known respiratory failure with baseline resting SpO2
3. Known WHO Class III or IV pulmonary hypertension
4. Severe intercurrent infection; active or infected wounds
5. Vaccination with any live attenuated vaccine within 30 days prior to trial registration/randomisation
6. Prior malignancy other than NSCLC (except if the tumour was a non-melanoma skin tumour that has been completely excised or in situ cervix carcinoma), unless have been treated with curative intent with no evidence of disease for > 3 years
7. Evidence of symptomatic brain metastases requiring treatment
8. Myocardial infarction, or unstable or uncontrolled disease or condition related to or impacting cardiac function (e.g., unstable
angina, congestive heart failure [New York Heart Association > class II]) within 1 year of enrolment
9. Venous thromboembolism within the last 6 months